Russell D. Cohen to Drug Administration Schedule
This is a "connection" page, showing publications Russell D. Cohen has written about Drug Administration Schedule.
Connection Strength
0.356
-
Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006 Aug 01; 24(3):465-74.
Score: 0.062
-
MLN-02 in IBD: is "super-selective" really super? Gastroenterology. 2006 May; 130(6):1923-4.
Score: 0.061
-
Medical management of severe ulcerative colitis. Gastroenterol Clin North Am. 2004 Jun; 33(2):235-50, viii.
Score: 0.054
-
Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm Bowel Dis. 2001 May; 7 Suppl 1:S17-22.
Score: 0.043
-
Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. Aliment Pharmacol Ther. 2020 03; 51(6):637-643.
Score: 0.039
-
Real-World Experience with Tofacitinib in IBD at a Tertiary Center. Dig Dis Sci. 2019 07; 64(7):1945-1951.
Score: 0.037
-
Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis. 2018 03 19; 24(4):849-860.
Score: 0.035
-
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013 Mar; 19(3):621-6.
Score: 0.025